Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Replimune Group, Inc. (REPL)

Biological Products, (no Disgnostic Substances)

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

500 UNICORN PARK
WOBURN, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/20/2018

Market Cap

696,878,280

Shares Outstanding

59,060,000

Weighted SO

59,059,343

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

NUVL --.--%

VTYX --.--%

ASND --.--%

UTHR --.--%

NVCT --.--%

LYRA --.--%

KRON --.--%

GOSS --.--%

KURA --.--%

Beta

1.2500

Last Div

0.0000

Range

4.92-21.32

Chg

-0.1000

Avg Vol

1176129

Mkt Cap

696878280

Exch

NASDAQ

Country

US

Phone

781 222 9600

DCF Diff

10.2212

DCF

-0.0212

Div Yield

0.0000

P/S

172.4093

EV Multiple

-2.6633

P/FV

1.6548

Div Yield %

0.0000

P/E

-3.2075

PEG

0.3836

Payout

0.0000

Current Ratio

13.4619

Quick Ratio

13.4742

Cash Ratio

4.2505

DSO

445.4589

DIO

-57.2805

Op Cycle

388.1784

DPO

112.9918

CCC

275.1866

Gross Margin

0.3095

Op Margin

-58.6175

Pretax Margin

-54.4884

Net Margin

-54.4312

Eff Tax Rate

0.0010

ROA

-0.4113

ROE

-0.5215

ROCE

-0.4745

NI/EBT

0.9990

EBT/EBIT

0.9296

EBIT/Rev

-58.6175

Debt Ratio

0.0918

D/E

0.1151

LT Debt/Cap

0.0958

Total Debt/Cap

0.1032

Int Coverage

-53.0524

CF/Debt

-3.7896

Equity Multi

1.2545

Rec Turnover

0.8194

Pay Turnover

3.2303

Inv Turnover

-6.3721

FA Turnover

0.0770

Asset Turnover

0.0076

OCF/Share

-2.6891

FCF/Share

-2.7885

Cash/Share

6.7806

OCF/Sales

-46.0282

FCF/OCF

1.0370

CF Coverage

-3.7896

ST Coverage

-47.6797

CapEx Coverage

-27.0337

Div&CapEx Cov

-27.0337

P/BV

1.6548

P/B

1.6548

P/S

172.4093

P/E

-3.2075

P/FCF

-3.6121

P/OCF

-3.7931

P/CF

-3.7931

PEG

0.3836

P/S

172.4093

EV Multiple

-2.6633

P/FV

1.6548

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 26, 04:55 Replimune Announces Pricing of Upsized Public Offering GlobeNewswire Inc. Jul 30, 06:00 Anaveon appoints Dieter Weinand as Chair of its Board of Directors Benzinga Dec 06, 12:00 Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap GlobeNewswire Inc. Nov 03, 19:30 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherap

Revenue Product Segmentation